Lidco Share Discussion Threads

[willib2] 10/7/2017 22:08

That report must be absolutely devastating to John and Norbert.

[buywell3] 10/7/2017 16:20

LiDCO technology has been proved superior to the USA market leader Edwards Life Sciences , and second market leader Maquet ( owner of Pulsion/picco

This is why ICU Medical have done a deal with LiDCO re Cogent 2-in-1 Hemodynamic monitor.

It is also why LiDCO will get bought out

dyor

[willib2] 10/7/2017 11:14

Arf, but it does say whose technology they will use and that means its the one you aint got no money in and the one John doesn't recommend.

[arf dysg] 10/7/2017 10:45

buywell, it's strange that the headline asks a question and then DOESN'T ANSWER IT...




buywell3 (5086)

"Which company has the best technology for the assessment and management of patient Hemodynamic status and changes ?"


Ah, which company indeed? It's that clever trick of asking one question and answering a DIFFERENT question.





"Evidence-Based Summary: The Demonstrated Clinical Efficacy of the LiDCO PulseCO™ Algorithm..."

Well, now, this talks about the EFFICIENCY, but it certainly doesn't say that Lidco is the BEST.


Lidco! Lidco! Strong and Stable Algorithm!!! As opposed to Deltex's Calculation of Chaos!!!!

[arf dysg] 09/7/2017 14:56

willib2 (5082)

"Doggy You'll Note,Note not Mote."
- I note your correction


"Err When may ever apply, and If is very debatable."
- but you probably meant "never" not "ever"




buywell3 (5083)

“The clearance by the FDA means that medical institutions within the United States now have the opportunity to benefit ..."

No, it just means that the FDA thinks that Lidco's device doesn't actively kill people.



TrentEndBoy (5084) "A clear winner is emerging. LID could be taken over soon at this rate"

Yes, I think about 100,000 Deltex shares should do it.

[trentendboy] 09/7/2017 14:28

A clear winner is emerging. LID could be taken over soon at this rate

[buywell3] 08/7/2017 17:16

Cardiac Output Monitoring Devices Market: A Booming trend in Healthcare Analytics Industry
JUNE 15TH, 2017


''The major key players operating in cardiac output monitoring device market include Edwards Lifesciences Corporation, Cheetah Medical, PULSION Medical Systems SE, Philips Healthcare, LiDCO Group plc, Boston Scientific Corporation, GE Healthcare, and others. Bioreactance-based NICOM Cheetah Medical remains the topmost non-invasive market leader.''









JULY 6, 2017

FDA Clears New Advanced Hemodynamic Monitoring Platform for Market





Last month, the FDA granted 501(k) clearance to LiDCO to market its new advanced hemodynamic monitoring platform.

The device, named LiDCOunity v2, is used to monitor the amount of blood flowing in the body and to ensure vital organs are receiving the appropriate amount of oxygen through the titration of fluid and drug management.

“The clearance by the FDA means that medical institutions within the United States now have the opportunity to benefit from the next generation of hemodynamic technologies,” said Matt Sassone, CEO of LiDCO.

The device allows for minimally invasive monitoring by using an already existing arterial line, allowing physicians to add noninvasive capabilities to measure blood volume through the use of infrared light. It also allows for constant monitoring of level of consciousness in patients using one monitor. Some other features of the new platform include simultaneous access to multiple parameters, tools to assist in the improvement of patient care, and a larger screen for more options to view at once.

The FDA clearance opens the door for LiDCO’s expansion into the $100 million hemodynamic monitoring U.S. market, according to Mr. Sassone.

[willib2] 08/7/2017 17:15

Doggy You'll Note,Note not Mote.
Err When may never apply, and If is very debatable.

[doglover2003] 07/7/2017 22:26

willi

Yes I do ............... You'll mote "When" not "If".

[willib2] 07/7/2017 18:12

Doglover2003, Mmmmmm Do you remember making this post.

doglover2003 - 02 Aug 2016 - 08:31:29 - 8280 of 8884
When will DEMG overtake LID share price?

[doglover2003] 07/7/2017 11:52

Let It Drop

[buywell3] 06/7/2017 07:31

On a less flippant note re todays RNS

As I stated before , I believe the way that share options have been granted to the new CEO and other members of the BOD has been structured in such a way that the sale of the company will still benefit them as long as the sale price achieved meets stated limits.

Todays RNS states the new limits for share options to vest ( without the sale of the company) for the new CFO are 12p and 16p.

Correct me if I am wrong , but it looks very much like 20% plus of Matt Sassones options are already in the bag as they were granted some while ago , the first limit price for 20% was 8p , the next limit price 10p , then 12p to 16p.

Now I have NO problem whatsoever with the BOD now being incentivised to get the price going north by way of share options that have a link to the company being sold.

In fact I like it.

What I also like is that the new LID CFO has had experience in her last two posts of just that :

''LiDCO (AIM: LID), the hemodynamic monitoring company, confirms the appointment of Jill McGregor as Chief Financial Officer on the 3 July, further to the announcement made on the 1 March 2017.

Ms McGregor is a Chartered Accountant and has over 25 years' experience in a number of finance roles. Ms McGregor joins LiDCO after six years as Chief Financial Officer of Touch Bionics, a UK based provider of upper limb technologies, with operations in the USA and Germany which was recently acquired by Össur. Prior to this, Ms McGregor spent seven years at Optos plc, a provider of retinal imaging devices, as Group Financial Controller and then as Vice President and Director of Finance. Optos listed on the London Stock Exchange in 2006 and was acquired by Nikon in 2015.''

[willib2] 05/7/2017 21:41

Arf, U could be right, I couldnt be bothered to check previous old posts.
However I dont think any of those, particularly "The Saviour" would sit well with many of those that fell for his retoric.
Didnt he once inform us that his broker called him something like The Black Knight, he as always was full of himself.

[arf dysg] 05/7/2017 18:07

willib, I suspect that the last letter is a U, not an E, but that's only my guess.

Come to think of it, is that the Greek word for "Christ" ? The Saviour? The Anointed One? Just asking.

[willib2] 05/7/2017 11:39

buwell3, tell Mr Christoe to take a course on market potential and forget about ramping and the technical side.

[arf dysg] 05/7/2017 10:17

TrentEndBoy (5073): Tell him "there are non so blind as those that cannot see".

Ahem, the actual saying is more like "none so blind as those who WILL not see."

"cannot see" means that someone is literally blind. What you're trying to say is a comment about those who don't WANT to see.



By the way, it's "none" not "non" !!

[trentendboy] 05/7/2017 10:09

Remember Buywell, stand up to bullies.

The evil one is trying his usual mind games.

Tell him "there are non so blind as those that cannot see".

[buywell3] 05/7/2017 08:42

In reply to queries about 'clinical evidence, and the LiDCO technoly 'from another advfn board.

Check out the actual Clinical Evidence which proves that LiDCO technology obtains better outcomes for BOTH patients and hospitals.

The link below gives access to around 30 Clinical Papers , for a variety of different types of surgery involving THOUSANDS of patients and details the type of LiDCO Monitor used ( they offer several for minimally inasive , invasive , and non invasive ) each being preferred by the NHS for specific operation types.



You can view the details, and outcomes by clicking the 'View full summary' button

I have looked long and hard at Hemodynamic Monitoring avenues to invest in.

I decided and of course this is my opinion based upon my research and I always urge others to do their own research before making any decision to invest :

I decided that if the NHS continued to adopt LiDCO technology for operations within their hospitals more than other types of technology then I would follow their lead.

From my research LiDCO has continued to gain NHS Hemodynamic Market share for the last 3 years I have been looking so that it now stands at around 55% , and thus the biggest provider.

It should also be noted that this was WITHOUT being on the NHS Supply Chain list of NHS providers of equipment for Hemodynamic Monitoring purposes, as they only got on this list in around the middle 2016 ( so under a year I think), check out a recent post on the LID thread for the exact date.

So the way I see it is that now LiDCO do not have to go through the long winded NHS Tendering Process any more , their lead will be extended.

I also think their latest offering which has just been FDA cleared , LiDCO untiy v2 will be adopted by the NHS and go on the Supply Chain list.

My opinion is therefore that LiDCO will have a 60% NHS share of the Hemodynamic Monitoring NHS market in 12 months time.

dyor

All of the above could easily be seen by reading the LiDCO results and reports , looking at their new website, and doing a bit of creative Googling.

when I say dyor ... I urge folks to look at the competition.

Since this post has taken me a while to compose I hope you guys don't mind if I add it to the LID board, as I see several posters do.

I have taken a leaf out of their book.

[trentendboy] 05/7/2017 07:58

Must be one of your most wayward investments

[waywardlad] 04/7/2017 23:22

I knew you'd bite :)

[willib2] 04/7/2017 13:43

Ha-ha The Count posts and along comes one of his ardent admirers, Waywardlad.

[arf dysg] 04/7/2017 12:34

buywell3 (5065) "Sometimes posters adopt a challanging stance to illicit information"

"illicit" - illegal, prohibited, forbidden (opposite of "licit", i.e. legitimate, etc.)

"elicit" - obtain, get



I'll pretend not to notice "chall_a_nging" instead of "chall_e_nging".

[arf dysg] 04/7/2017 12:28

maxk (5064) "a balance sheet mostly made up of third party kit"


Really? Does LIDCO sell other people's products? How interesting.

I wonder what happens if you subtract the third-party products? I would hate to think that this would change a trend of INCREASING sales into a trend of DECREASING sales. It would be terrible if that were to happen. It would be so disappointing for LID shareholders. It might even render the High-Use Programme completely pointless. It might even make the High-Use Programme seem like a desperate attempt to offer a discount in the hope that it resulted in some sales.


"High-Use Programme" -

(1) a publicity campaign to persuade investors to believe that there is a high use of Lidco's products, but carefully worded so that it doesn't actually state that any particular quantity of sales exists;

(2) a discount programme, to persuade hospitals to buy some of Lidco's products, as apposed to none at all.